BGGS
RNA

Boussard & Gavaudan Gestion SAS’s Atrium Therapeutics RNA Stock Holding History

Boussard & Gavaudan Gestion SAS’s Portfolio RNA Stock Details RNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$447K Buy
+32,845
New +$429K 0.02% 83

Other funds holding RNA

SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CL
CRCM LP San Francisco, California $152M AUM 26.3% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Boussard & Gavaudan Gestion SAS's RNA Position: Q2 2026 in Review

Boussard & Gavaudan Gestion SAS opened a new position in Atrium Therapeutics (RNA) in Q2 2026: 32,845 shares worth $447K. The stake represents 0.02% of the portfolio and ranks #83 among its holdings.

153 funds tracked by Wall St. Rank hold RNA as of Q2 2026.

  • Boussard & Gavaudan Gestion SAS held 32,845 shares of Atrium Therapeutics worth $447K as of Q2 2026.
  • Atrium Therapeutics was a new Boussard & Gavaudan Gestion SAS position in Q2 2026.
  • Atrium Therapeutics made up 0.02% of Boussard & Gavaudan Gestion SAS's portfolio in Q2 2026, its #83 holding.
  • 153 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q2 2026.

Based on Boussard & Gavaudan Gestion SAS's 13F filing for Q2 2026, filed 19 Aug 2026.